A new treatment approach for lethal drug-resistant bacterial skin infections

Active Grant Awarded

Award ID
R41AI197653
Recipient
Awarding agency
Obligated
$303,933

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 21% complete
Place of performance
Dallas, TX 75230, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Mirofend LLC a grant totaling $303,933 on September 9, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The program supports biomedical research on infectious, immunologic, and allergic diseases. Under this Phase I application, Mirofend will solidify the efficacy of a patent-pending approach for managing Staphylococcus aureus infections, using in vitro assays and several mouse models of infection. The work is intended to advance commercialization of a new treatment for lethal bacterial skin infections, including drug-resistant strains. The full $303,933 is obligated. The period of performance runs from September 9, 2026, through August 31, 2027. Place of performance is Dallas, Texas 75230, USA.

Description

Abstract
Staphylococcus aureus soft tissue and skin infections affect seven-to-ten percent of hospitalized patients and skin infections are the third most common reason for presentation to the emergency room. Most infections of the skin are caused by S. Aureus, with men having higher rates of infection with S. Aureus compared to women. Adding to the burden of disease posed by these pathogens has been the development of antibiotic-resistant strains of bacteria such as methicillin-resistant S. Aureus (MRSA). Furthermore, S. Aureus exacerbates the inflammatory skin condition, atopic dermatitis (ad), that affects thirteen percent of adults and twenty percent of children in the united states. The pathogenesis of ad is incompletely understood, and there is an increasing appreciation for the contributions of the microbiome in ad pathogenesis. During ad flares, S. Aureus expands and exacerbates inflammatory responses and skin damage. Given the societal burden of S. Aureus and the expanding antibiotic resistance, new treatment approaches are needed. We have now discovered a patent- pending approach for the management of S. Aureus infections. In this phase I application we will solidify the efficacy of this treatment through the use of in vitro assays and several mouse models of infection. The work proposed will fuel the commercialization of a new approach for the treatment of lethal bacterial infections in the skin.

Quick answers

Who received award R41AI197653?

R41AI197653 was awarded to Mirofend LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.

How much is award R41AI197653 worth?

$303,933 has been obligated on R41AI197653.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award